DC Chemicals Limited
China
Product Name: MR 409
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

1445155-39-4

1445155-39-4 structure

Name: MR 409
Chemical Name: MR 409
CAS Number: 1445155-39-4
Molecular Formula: C₁₅₃H₂₅₂N₄₄O₄₃
Molecular Weight: 3395.91
Catalog: Research Areas Cancer
Create Date: 2022-03-28 17:10:38
Modify Date: 2025-08-25 15:10:13
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].

Name	MR 409

Description	MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
In Vitro	One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo[1]. MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)[2]. MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2[2]. MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner[3]. MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect[3]. MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect[3]. MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion[4]. Western Blot Analysis[2] Cell Line: BPAEC Concentration: 1 μM Incubation Time: 24, 48 and 72 hours Result: Significantly suppressed p53 expression levels after 48 and 72 hours of treatment.
In Vivo	MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice[3]. MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice[3]. Animal Model: Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)[3] Dosage: 5 µg Administration: Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution Result: Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.
References	[1]. Rosemeire M Kanashiro-Takeuchi, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39. [2]. Mohammad A Uddin, et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 2019;7(4):1669989. [3]. Lucia Recinella, et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci Rep. 2021 Jan 28;11(1):2530. [4]. Yueyang Liu, et al. Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2109600118.

Molecular Formula	C₁₅₃H₂₅₂N₄₄O₄₃
Molecular Weight	3395.91

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1445155-39-4	62509-10-8
185213-55-2	61849-16-9
2374703-19-0	61849-15-8
185308-24-1	147614-21-9
207403-36-9	59203-73-5
1314973-05-1	1192471-90-1
1270401-06-3	1270090-55-5
1270504-00-1	1270580-31-8
1270534-23-0	96693-87-7
1270331-71-9	1270440-77-1